Renal Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore our latest breakthroughs in Renal Cancer Research. Learn more about our innovative pipeline today! @ Renal Cancer Pipeline Outlook
Key Takeaways from the Renal Cancer Pipeline Report
In February 2025:- H. Lee Moffitt Cancer Center and Research Institute:- The treatment is organized into blocks of 9 weeks, with pembrolizumab treatment planned for weeks 1, 4 and 7. On the second and third blocks, interleukin-2 is added, for 5 doses at a time, one dose every 8 hours, on a weekly schedule on the two weeks after the week 1 and the week 4 pembrolizumab doses.
In February 2025:- Merck Sharp & Dohme LLC:- This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR).
DelveInsight's Renal Cancer pipeline report depicts a robust space with 75+ Renal Cancer companies working to develop 80+ pipeline therapies for Renal Cancer treatment.
The leading Renal Cancer Companies such as Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
Promising Renal Cancer Pipeline Therapies such as Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.
Stay informed about the cutting-edge advancements in Renal Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Renal Cancer Clinical Trials Assessment
Renal Cancer Emerging Drugs Profile
Atezolizumab : Genentech
Atezolizumab is a monoclonal antibody. It is designed to bind with a protein called PD-L1 expressed on tumor cells and tumor-infiltrating immune cells by blocking its interactions with both PD-1 and B7.1 the drug candidate are programmed cell death-1 ligand-1 inhibitors. Currently it is in Phase III stage of clinical trial evaluation to treat Renal Cancer.
Olaparib: AstraZeneca
Olaparib is a potent and orally active poly (ADP-ribose) polymerase PARP inhibitor thereby blocking the repair of single-strand DNA breaks resulting in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway – homologous recombination being developed for the treatment of renal cell carcinoma. Currently being evaluated in the Phase II studies.
MK-4830 : Merck & Co., Inc
MK-4830 is an investigational first-in-class human monoclonal antibody that inhibits the binding of immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with Agenus Inc. Currently the drug is being evaluated in Phase II for the treatment of Renal Cancer.
ALLO-316 : Allogene Therapeutics
ALLO-316, an AlloCAR T™ investigational product that targets CD70, which is highly expressed in renal cell carcinoma (RCC). CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors the drug candidate has received Fast Track Designation (FTD) from U.S FDA based on the potential of ALLO-316 to address the unmet need for patients with difficult to treat renal cell carcinoma. The drug is in Phase I stage of clinical trials.
Learn more about Renal Cancer Drugs opportunities in our groundbreaking Renal Cancer Research and development projects @ Renal Cancer Unmet Needs
Renal Cancer Companies
Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others
Renal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
intravenous
Subcutaneous
Topical
Renal Cancer Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Discover the latest advancements in Renal Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Renal Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Renal Cancer Pipeline Report
Coverage- Global
Renal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Renal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Renal Cancer Companies- Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
Renal Cancer Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.
For a detailed overview of our latest research findings and future plans, read the full details of Renal Cancer Pipeline on our website @ Renal Cancer Drugs and Companies
Table of Content
Introduction
Renal Cancer Executive Summary
Renal Cancer: Overview
Renal Cancer Pipeline Therapeutics
Renal Cancer Therapeutic Assessment
Late Stage Products (Phase III)
Comparative Analysis
Atezolizumab: Genentech
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Olaparib: AstraZeneca
Early Stage Products (Phase I)
Allogene Therapeutics: ALLO-316
Inactive Products
Renal Cancer Companies
Renal Cancer Products
Renal Cancer Unmet Needs
Renal Cancer Market Drivers and Barriers
Renal Cancer Future Perspectives and Conclusion
Renal Cancer Analyst Views
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
a day ago
- CTV News
‘Live my life out loud': P.E.I. woman battling cancer encourages others to ‘just live'
Prince Edward Islander Michelle Hughes is documenting her cancer journey daily, while encouraging others to live and embrace the joy in everyday. (Source: Facebook / My Journey to Just Live) Michelle Hughes is on a journey to 'just live,' and she's encouraging others to do the same. The 38-year-old Prince Edward Islander from Cornwall is a mother of three young children. She's also battling stage four incurable cancer. Four years ago, and three weeks after giving birth to her third child, Hughes was diagnosed with stage four Epithelioid hemangioendothelioma, or EHE. The Canadian Cancer Society describes EHE as 'a cancerous (malignant) tumour that starts in the blood vessels.' At the time, an oncologist gave her three to five years to live. 'Obviously, I was heartbroken and devastated and envisioned my husband raising our children all by himself. And that oncologist really left a mark in my heart thinking that I need to savour every moment moving forward for these children because they're not going to remember me,' explains Hughes in an interview with CTV Atlantc. 'Thankfully, I came about another oncologist who was a sarcoma cancer specialist at the Princess Margaret (Cancer Centre). And she had said, 'Sure, you could die in those five years. You could die in three years. But I have patients living for decades. And I have hope for you, so I want you to just live.'' The conversation was a turning point for Hughes. 'That's when I realized that tomorrow is not promised to anybody. And I took her slogan, and ran with it, literally. It changed my life. I decided to live my life out loud.' Michelle Hughes Four years ago, Michelle Hughes was diagnosed with stage four Epithelioid hemangioendothelioma, or EHE. (Source: Facebook / My Journey to Just Live) She started by documenting her cancer battle online under the banner My Journey To Just Live. She also wanted to create daily posts with her husband, Ty, and young children as a family keepsake. 'For them to look back and see all the fun memories that we've captured, and all the joy that we've been chasing as a family. But it's evolved into so much more as people actually started to read it and to follow along. And I never envisioned that in a million years, so that's not at all what I set out when I started my journey to just live.' Michelle Hughes Michelle Hughes is pictured with her husband and three children. (Source: Facebook / My Journey to Just Live) Along with challenging herself physically, Hughes' decision to 'just live' included a mind shift change. 'Like, things that you used to just take for granted in life are something that you value every moment of every day,' she says. 'For example, walking my children to the bus stop is my favourite part of my everyday, because when I get to stand there and see my two girls looking out the window back at me and I'm there smiling at them, it's amazing. It's a beautiful feeling because my four-year-old son's hand, who I'm holding, he might not get that opportunity.' Michelle Hughes Michelle Hughes is pictured with her son. (Source: Facebook / My Journey to Just Live) Making an impact People following her journey include over 96,000 on Facebook and 446,000 on Instagram. Her daily posts serve as a diary entry: experiences with the family, daily errands, feelings, life lessons and self reflection. 'It gives a raw, real perspective of what it's like in my journey to just live because, you know, we could meet somebody else who has stage four cancer as well, but we might be walking completely different lives,' says Hughes. 'So, I always just reiterate that this is my journey to just live, and it's been beautiful to connect with cancer survivors and survivors around the world, and just people suffering with chronic health conditions, and hearing from them how me living my life out loud has supported them, and it's been so beautiful to be a part of.' Michelle also has a podcast, and was featured in a documentary called The Journey Home, where she ran, cycled and swam a total of 120 kilometres from the Moncton Hospital to her home in P.E.I. Michelle Hughes Michelle Hughes is pictured in a gym. (Source: Facebook / My Journey to Just Live) Forward thinking Hughes is choosing to 'just live' alongside battling cancer. 'Unfortunately, right now, over the last few weeks my liver pain has come back, and it's out of the norm for me. I'll be going in my CT scan again next week.' Hughes says the cancer she has is 'considered incurable' and there isn't a 'standard protocol' for treating it. In the coming weeks, she'll begin participating in a new clinical trial out of Toronto. 'It is not a pharmaceutically sponsored trial. So, all costs will be on us, but it's not stopping us. We're moving forward because we have hope that it's going to help bring me back to stability as my cancer has been progressing since last year. It's been growing every three months.' Despite these challenges, Hughes isn't slowing down. While preparing for the clinical trial to begin, she is also planning the third annual Just Live Fun Run in Cornwall, P.E.I. on Sunday, Aug. 24. More than 1,500 people have registered, and 500 race kits have been shipped to 12 countries for people who will be participating virtually. 'Last year alone we raised $108,000. All proceeds go to Sarcoma Cancer Foundation of Canada, where they match every dollar.' Michelle Hughes Michelle Hughes is planning the third annual Just Live Fun Run in Cornwall, P.E.I. on Sunday, Aug. 24. (Source: Facebook / My Journey to Just Live) Hughes also has her sights set on her next endurance event in 2026. 'Next year will be my five year 'cancerversary' date. We have something really special we'll be announcing in the coming months. It's going to be so difficult, but I think it's what my body needs and what I mentally need to get through this clinical trial because, obviously, I'm scared, and it's going to be a rough journey. But I need something physically to set my body up for success and to mentally keep me in the game. And I'm really excited to announce this next endurance event that I'm about to do.' As for anyone looking to 'just live' her advice is simple. 'Just live in the moment. It doesn't cost money. You don't have to exert yourself. It's literally just standing in a moment that you don't know you'll have forever and just savouring it.' For more P.E.I. news, visit ourdedicated provincial page.
CBC
a day ago
- CBC
Teammates, friends mourn Scarborough basketball star in the making
When Adeena Razzaq showed up at the Jarvis Collegiate Institute basketball court in Toronto this week, she arrived wearing her brother's clothes. "Ever since I was a kid I've been wearing his clothes," the 18-year-old told CBC Toronto. "He got mad at me a few times, but he got used to it." It's one of the many ways she'll hold onto memories of her older brother Affan, who died earlier this month from cancer at age 20. Then there's his sport — the game that drew him in from the time he was six or seven years old, and which he was on the road to pursuing professionally. "Whenever I see basketball, I just see him," said Razzaq. Standing at six feet eight inches, Scarborough's Affan Razzaq had accepted a scholarship to play basketball at Northern Oklahoma College and hoped to take his place in the NBA draft one day. Last December, he was diagnosed with brain cancer, but continued to train even as he underwent aggressive treatment for the disease. He last stepped onto a court at Jarvis C.I. in July, just weeks before he died. A 'really humble' teammate Omar Nicholls, one of Affan's coaches, says the young man's height and skills helped rack up wins at many tournaments and championships over the years, but that it was his abilities as a teammate that stood out. "A really humble kid, really nice, never argued with anybody, never cursed," said Nicholls. "He's just an amazing kid to be around." Nicholls, who co-founded a program called NuStep Basketball with his partner Elisha Romain in 2013, helped train Affan for the last six years, watching as he strove to reach the level of his basketball heroes like Kevin Durant. The couple were the first to be told about the cancer diagnosis outside the Razzaq family. "To know that we meant that much to him was a lot," said Romain, who said she dove headfirst into researching Affan's disease and trying to find ways to help him feel grounded and supported. Like his family, Nicholls describes Affan as a fighter. "In the hospital, he kept on talking about, you know, hopefully he can get out of here soon, get discharged," he said. "Right to the very end. He said, 'I'm going to get out of here.'" An outpouring of grief Affan's funeral, held on Monday in Pickering, Ont., brought out scores of former teammates and friends, says longtime family friend Ibrahim Daniyal. "The mosque management was amazed to see how many Canadian youth came to say goodbye to him. It was not one community. It was Canadians of all creeds, faiths, ethnicities," Daniyalsaid. That support is a source of some comfort for the Razzaq family, including Affan's parents. "His mother is just praying for him. That's what she's doing all the time," said Daniyal. Affan's younger brother, 14-year-old Ayaan Razzaq, said he's lost both a protector and a role model. "He was kind of the person who just wanted to look out for me, and … really just wanted the best for me," he said. Outside of his grieving family and friends, some of who Affan Razzaq was lives on online, where he filled out a LinkedIn profile last year, complete with a photo of himself mid-dunk. "Kobe Bryant once said 'The moment you give up, is the moment you let someone else win.' I live by this quote everyday," wrote Affan. "My dream is to make it to the NBA, and I wont give up until I make it."
National Post
3 days ago
- National Post
Nike co-founder Phil Knight and wife pledge record US$2B to Oregon cancer centre
PORTLAND, Ore. — Nike co-founder Phil Knight and his wife, Penny Knight, have pledged to donate US$2 billion to Oregon Health & Science University's Knight Cancer Institute, the school announced Thursday, describing it as the largest single gift to a U.S. university. Article content 'This gift is an unprecedented investment in the millions of lives burdened with cancer, especially patients and families here in Oregon,' OHSU President Shereef Elnahal said in a statement. Article content Article content The donation will help ensure patients have access to various resources, including psychological, genetic and financial counselling, symptom management, nutritional support and survivorship care, the university statement said. Article content Article content The university described it as the 'largest single donation ever made to a U.S. university, college or academic health center.' It surpasses the US$1.8 billion given by Michael Bloomberg to Johns Hopkins in 2018, described by that university at the time as the largest single contribution to a U.S. university. Article content Bloomberg also donated an additional US$1 billion to Johns Hopkins last year, covering tuition, living expenses and fees for students from families under certain income levels. Article content The magnitude of the donation will allow the Knight Cancer Institute to become a self-governed entity with its own board of directors within OHSU, the university said. Article content Article content Knight is Oregon's richest man. In 2013, he and his wife pledged US$500 million to the cancer institute if the university matched it within two years. The match was met following US$200 million in bonds from the Oregon Legislature, US$100 million from then-chair of Columbia Sportswear Gert Boyle, and donations from some 10,000 people, the university said. Article content
